The worldwide market for obesity drugs represents an extremely attractive opportunity, even more so now that Sanofi-Aventis rimonabant has failed to gain FDA approval.
A surprise to no one, the incidence of obesity and morbid obesity is on the rise, pushing an aggregate prevalence in excess of 300 million patients globally, and outpaced in growth only [...]
bookmark to
